SCHEMBL4600210

SCHEMBL4600210

CCCOc1ccc(Br)cc1C(=O)OC

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HPGD P15428 4/20 0.51
HSD17B10 Q99714 2/20 0.50
AR P10275 1/20 0.49
PTGDR2 Q9Y5Y4 1/20 0.49
SMN1; SMN2 Q16637 4/20 0.45
MAPT P10636 3/20 0.45
ALDH1A1 P00352 3/20 0.45
HSP90AA1 P07900 2/20 0.45
CYP1A2 P05177 1/20 0.45
CYP2C9 P11712 1/20 0.45
CYP2C19 P33261 1/20 0.45
HTT P42858 3/20 0.45
KDM4E B2RXH2 2/20 0.45
LMNA P02545 2/20 0.45
NPC1 O15118 1/20 0.45
RAB9A P51151 1/20 0.45
NPSR1 Q6W5P4 1/20 0.45
NR4A2 P43354 1/20 0.44
GAA P10253 2/20 0.44
LCLAT1 Q6UWP7 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2772497 0.93 SMN1; SMN2 (0.49) HPGDHSD17B10PTGDR2SMN1; SMN2MAPT
SCHEMBL2723239 0.88 ALDH1A1 (0.56) HPGDHSD17B10ARPTGDR2SMN1; SMN2
SCHEMBL16997485 0.87 HSD17B10 (0.49) HPGDHSD17B10PTGDR2SMN1; SMN2MAPT
SCHEMBL7371844 0.86 PTGDR2 (0.56) HPGDHSD17B10ARPTGDR2SMN1; SMN2
SCHEMBL20471949 0.85 HSD17B10 (0.48) HPGDHSD17B10PTGDR2SMN1; SMN2MAPT
SCHEMBL17973700 0.84 PTGDR2 (0.68) HPGDHSD17B10ARPTGDR2SMN1; SMN2
SCHEMBL27039988 0.84 ALDH1A1 (0.51) HPGDHSD17B10PTGDR2SMN1; SMN2MAPT
SCHEMBL20472002 0.84 HSD17B10 (0.47) HPGDHSD17B10PTGDR2SMN1; SMN2MAPT
SCHEMBL5927172 0.83 HPGD (0.52) HPGDHSD17B10ARPTGDR2SMN1; SMN2
SCHEMBL11328546 0.83 PLA2G2A (0.48) HPGDHSD17B10SMN1; SMN2MAPTALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240041837-A1 TRIAZOLONE COMPOUNDS AND USES THEREOF TEMPEST THERAPEUTICS, INC. 2024-02-08 US disclosed
US-11666557-B2 Triazolone compounds and uses thereof TEMPEST THERAPEUTICS, INC. (US) 2023-06-06 US disclosed
US-11666557-B2 Triazolone compounds and uses thereof TEMPEST THERAPEUTICS, INC. (US) 2023-06-06 US disclosed
US-11666557-B2 Triazolone compounds and uses thereof TEMPEST THERAPEUTICS, INC. (US) 2023-06-06 US disclosed
US-20200138790-A1 TRIAZOLONE COMPOUNDS AND USES THEREOF TEMPEST THERAPEUTICS, INC. 2020-05-07 US disclosed
US-20200138790-A1 TRIAZOLONE COMPOUNDS AND USES THEREOF TEMPEST THERAPEUTICS, INC. 2020-05-07 US disclosed
US-10568871-B2 Triazolone compounds and uses thereof TEMPEST THERAPEUTICS, INC. (US) 2020-02-25 US disclosed
US-10568871-B2 Triazolone compounds and uses thereof TEMPEST THERAPEUTICS, INC. (US) 2020-02-25 US disclosed
EP-2935228-B9 TRIAZOLONE COMPOUNDS AND USES THEREOF INCEPTION 2 INC (US) 2017-12-06 EP disclosed
EP-2935228-B9 TRIAZOLONE COMPOUNDS AND USES THEREOF INCEPTION 2 INC (US) 2017-12-06 EP disclosed
US-20150080412-A1 TRIAZOLONE COMPOUNDS AND USES THEREOF INCEPTION 2, INC. (US) 2015-03-19 US disclosed
US-20150080412-A1 TRIAZOLONE COMPOUNDS AND USES THEREOF INCEPTION 2, INC. (US) 2015-03-19 US disclosed
EP-2822931-A1 TRIAZOLONE COMPOUNDS AND USES THEREOF Inception 2, Inc. (US) 2015-01-14 EP disclosed
WO-2014099503-A1 TRIAZOLONE COMPOUNDS AND USES THEREOF INCEPTION 2, INC. (US) 2014-06-26 WO disclosed
WO-2014099503-A1 TRIAZOLONE COMPOUNDS AND USES THEREOF INCEPTION 2, INC. (US) 2014-06-26 WO disclosed
WO-2013134562-A1 TRIAZOLONE COMPOUNDS AND USES THEREOF INCEPTION 2, INC. (US) 2013-09-12 WO disclosed
WO-2013134562-A1 TRIAZOLONE COMPOUNDS AND USES THEREOF INCEPTION 2, INC. (US) 2013-09-12 WO disclosed
EP-1912970-A2 ACYLTRYPTOPHANOLS FOR FERTILITY CONTROL Bayer Schering Pharma Aktiengesellschaft (DE) 2008-04-23 EP disclosed
US-20070060573-A1 Acyltryptophanols BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2007-03-15 US disclosed
WO-2007017289-A2 ACYLTRYPTOPHANOLS FOR FERTILITY CONTROL BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2007-02-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11666557-B2 Triazolone compounds and uses thereof PPARA, PPARG, PPARD HPGD 2329/4885HSD17B10 497/4885AR 51/4885
US-20240041837-A1 TRIAZOLONE COMPOUNDS AND USES THEREOF PPARA, PPARG, PPARD HPGD 2329/4885HSD17B10 497/4885AR 51/4885
US-10568871-B2 Triazolone compounds and uses thereof PPARA, PPARG, PPARD HPGD 2329/4885HSD17B10 497/4885AR 51/4885
US-20200138790-A1 TRIAZOLONE COMPOUNDS AND USES THEREOF PPARA, PPARG, PPARD HPGD 2329/4885HSD17B10 497/4885AR 51/4885
US-20150080412-A1 TRIAZOLONE COMPOUNDS AND USES THEREOF PPARA, PPARG, PPARD HPGD 1996/4885HSD17B10 418/4885AR 37/4885
US-20070060573-A1 Acyltryptophanols FSHR, NPY1R, NPY2R HPGD 2557/4885HSD17B10 2116/4885AR 133/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.